|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Reader, the summer is upon us (if it ever stops raining) and it’s time to take a bit of a respite. So this is the last posting until September 2006. See you then. Have a happy and safe summer, Shara Rosen AviaraDx entered into a research collaboration with the Massachusetts General Hospital (MGH) Cancer Center to conduct a broad molecular profiling program to determine genes, gene signatures and polymorphisms that correlate with response to specific therapeutic agents in a wide range of different cancers. The initiative aims to identify and commercialize tumor biomarkers that predict which patients may respond to targeted drugs. Bruker Daltonics introduced its new ClinProTools 2.1 and flexImaging 2.0 software versions. These integrated software packages allow biologists and clinical researchers to merge statistical analysis on MALDI-TOF profiling spectra with molecular images of tissue distributions of peptide and protein biomarkers. This analysis capability is now available on MALDI Molecular Imager. Cepheid was awarded the CE mark for the Smart EBV (Epstein-Barr Virus) Assay for clinical diagnostic use on the SmartCycler System. Smart EBV is intended for rapid detection and quantitation of EBV viral load to detect post-transplant lymphoproliferative disorder (PTLD). Cepheid entered into a collaboration with the Foundation for Innovative Diagnostics (FIND) to develop a rapid molecular diagnostic test for tuberculosis (TB) in sputum and simultaneously determine whether the organisms are drug resistant. Dr. David Alland at the University of Medicine and Dentistry of New Jersey will also be collaborating with Cepheid. The test will be designed to run on Cepheid's GeneXpert System. Enzo Biochem announced it plans to enter into the cytogenetics market by producing newly patented single copy DNA probes that can identify the minutest strands of DNA. Enzo plans to combine the probes with its proprietary signal amplification technologies. The DNA technology was licensed from Kansas City's Children's Mercy Hospitals & Clinics. Genzyme launched the FLT3 Mutation Analysis and WT1 RQ-PCR molecular tests for acute myelogenous leukemia (AML). FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. The WT1 RQ PCR test allows physicians to monitor AML patients for early relapse during and following therapy. Illumina and deCODE formed an alliance to develop and commercialize DNA diagnostics for the risk of heart attack, type 2 diabetes, and breast cancer. The alliance will employ Illumina's platform for high-multiplex single-nucleotide polymorphism (SNP) genotyping to develop tests for gene variants deCODE has chosen. The diagnostic panels will be marketed by Illumina on the BeadXpress platform. PerkinElmer acquired Spectral Genomics. Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: June 5, 2006 |
![[Page Banner Image]](images/hmole.gif){kind=small}
